Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Developing treatment for sickle cell disease.

Martin H Steinberg1, Carlo Brugnara

  • 1Boston University School of Medicine, Boston, Massachusetts 02118, USA. msteinberg@medicine.bu.edu

Expert Opinion on Investigational Drugs
|May 9, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease.

The New England journal of medicine·2026
Same author

Modeling Genetic Diversity in Sickle Cell Disease Reveals Heterogeneous Responses to HbF-Inducing Therapies.

bioRxiv : the preprint server for biology·2026
Same author

PGC-1α agonism via oral administration of ZLN005 induces fetal hemoglobin and is antisickling in sickle mice.

Blood advances·2026
Same author

Letter to the Editor.

Drug testing and analysis·2026
Same author

One cell at a time: HbF distribution in sickle cell disease.

Blood advances·2026
Same author

One cell at a time: HbF distribution in sickle cell disease.

Blood advances·2026

Sickle cell disease stems from sickle hemoglobin polymerization, damaging red blood cells and blood vessels. Treatments aim to inhibit polymerization, prevent cell dehydration, and reduce cell-vessel interactions.

Area of Science:

  • Hematology
  • Vascular Biology
  • Molecular Medicine

Background:

  • Sickle cell disease (SCD) pathophysiology is driven by the polymerization of sickle hemoglobin (HbS).
  • This polymerization leads to red blood cell (RBC) sickling, causing cellular damage and vaso-occlusion.
  • Numerous SCD complications arise secondary to HbS polymer-induced injury to RBCs and the vasculature.

Purpose of the Study:

  • To elucidate the core pathophysiological mechanisms of sickle cell disease.
  • To identify key targets for pharmacological intervention in SCD management.

Main Methods:

  • Review of existing literature on sickle cell disease pathophysiology.
  • Analysis of the molecular mechanisms of sickle hemoglobin polymerization.
  • Examination of the cellular and vascular consequences of sickled erythrocytes.

Related Experiment Videos

Main Results:

  • Sickle hemoglobin polymerization is the primary molecular event initiating SCD.
  • Sickled erythrocytes cause endothelial damage and vaso-occlusive events.
  • RBC dehydration exacerbates HbS polymerization and cellular damage.

Conclusions:

  • Understanding HbS polymerization is crucial for SCD pathophysiology.
  • Therapeutic strategies should target HbS polymerization, RBC hydration, and erythrocyte-endothelial interactions.
  • Pharmacological interventions aim to inhibit HbS polymerization, correct RBC dehydration, and prevent vaso-occlusion.